Dyslipidemia is the multiple lipid metabolic disorders which is one of the high risk factors for the atherosclerotic diseases. It increases the morbidity and mortality and therefore, must be treated with antilipidemic agents. HMG-Co A reductase inhibitors (statins), one of many antidyslipidemic agen...
Dyslipidemia is the multiple lipid metabolic disorders which is one of the high risk factors for the atherosclerotic diseases. It increases the morbidity and mortality and therefore, must be treated with antilipidemic agents. HMG-Co A reductase inhibitors (statins), one of many antidyslipidemic agents, have shown to be significant improvement from the various cholesterol levels. Especially, data from many comparative trials suggest that rosuvastatin is more effective than atorvastatin among many other statins. The aims of this study were to evaluate the efficacy and safety between rosuvastatin and atorvastatin in the treatment of Korean patients with dyslipidemia. Currently the Korean Society of Lipidology and Atherosclerosis based on the Korean health screening data suggests that Korean patients with dyslipidemia should be treated by the target cholesterol levels according to the Adult Treatment Panel III guidelines of the US National Cholesterol Education Program (NCEP-ATP III). We reviewed retrospectively all medical histories of the total 392 dyslipidemic patients with atorvastatin or rosuvastatin from June 1st, 2004 to August 31st, 2006 in Chungbuk National University Medical Center. Patients were classified as total 4 groups by the NCEP-ATP III Guidelines. The numbers of enrolled patients were each 5 mg atorvastatin (n=34), 10 mg atorvastatin (n=148), 5 mg rosuvastatin (n=94) and 10 mg rosuvastatin (n=82). In comparison between groups, rosuvastatin groups in the lowering LDL-C had better efficacies, and the results were each 22% (5 mg atorvastatin), 33.3% (10 mg atorvastatin), 35% (5 mg rosuvastatin) and 41.3% (10 mg rosuvastatin) with the dose relationship (P=0.000). Rosuvastatin groups also have shown to be more significantly reducing Total Cholesterol levels compared to atorvastatin groups with the no dose relationship (P=0.000). In the lowering of non-HDL cholesteroles, rosuvastatin groups showed significantly better efficacies than atorvastatin with the dose-relationship (P=0.000). Each medication groups did not demonstrate the differences in the changing of HDL cholesterol and triglyceride levels (P=0.096, 0.309, respectively). In conclusion, rosuvastatin was better efficacious than atrovastatin in reducing LDL-C Total Chol, and Tg. Therefore, rosuvastatin is a good antilipidemic agents for Korean patients with dyslipidemia and it can use to minimize the morbidity and mortality related to the cardiovascular diseases in Korean.
Dyslipidemia is the multiple lipid metabolic disorders which is one of the high risk factors for the atherosclerotic diseases. It increases the morbidity and mortality and therefore, must be treated with antilipidemic agents. HMG-Co A reductase inhibitors (statins), one of many antidyslipidemic agents, have shown to be significant improvement from the various cholesterol levels. Especially, data from many comparative trials suggest that rosuvastatin is more effective than atorvastatin among many other statins. The aims of this study were to evaluate the efficacy and safety between rosuvastatin and atorvastatin in the treatment of Korean patients with dyslipidemia. Currently the Korean Society of Lipidology and Atherosclerosis based on the Korean health screening data suggests that Korean patients with dyslipidemia should be treated by the target cholesterol levels according to the Adult Treatment Panel III guidelines of the US National Cholesterol Education Program (NCEP-ATP III). We reviewed retrospectively all medical histories of the total 392 dyslipidemic patients with atorvastatin or rosuvastatin from June 1st, 2004 to August 31st, 2006 in Chungbuk National University Medical Center. Patients were classified as total 4 groups by the NCEP-ATP III Guidelines. The numbers of enrolled patients were each 5 mg atorvastatin (n=34), 10 mg atorvastatin (n=148), 5 mg rosuvastatin (n=94) and 10 mg rosuvastatin (n=82). In comparison between groups, rosuvastatin groups in the lowering LDL-C had better efficacies, and the results were each 22% (5 mg atorvastatin), 33.3% (10 mg atorvastatin), 35% (5 mg rosuvastatin) and 41.3% (10 mg rosuvastatin) with the dose relationship (P=0.000). Rosuvastatin groups also have shown to be more significantly reducing Total Cholesterol levels compared to atorvastatin groups with the no dose relationship (P=0.000). In the lowering of non-HDL cholesteroles, rosuvastatin groups showed significantly better efficacies than atorvastatin with the dose-relationship (P=0.000). Each medication groups did not demonstrate the differences in the changing of HDL cholesterol and triglyceride levels (P=0.096, 0.309, respectively). In conclusion, rosuvastatin was better efficacious than atrovastatin in reducing LDL-C Total Chol, and Tg. Therefore, rosuvastatin is a good antilipidemic agents for Korean patients with dyslipidemia and it can use to minimize the morbidity and mortality related to the cardiovascular diseases in Korean.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
문제 정의
s. Therefore we performed on this study to evaluate the efficacy and safety of rosvasta- tin and atorvastatin for the treatment of Korean dyslipi demic patients. So we can apply the results for effective and safe pharmacotherapy of Korean dyslipidemic patients with statins in the future.
제안 방법
And then after 6weeks later, re-eval- 니ate each HDL-C of patients who were taking either atorvastatin 5, atorvastatin 10, rosuvastatin 5 or ros니vast% tin 10mg. And then calculates the differences of the both serum lipid lev이s by subtraction of HDL-C value from TC v기니e of 1).
That is, all selected patients were classified and decided the target goal by NCEP-ATP III guideline. And then, each classified group was evaluated for sex, age (M >= 45 years, F 그 = 55 years), weight, height, Body Mass Index (BMI) of patients, positive risk factors as cigarette smoking, hypertension, diabetes mellitus, coronary artery disease (CHD), HDL-C (low < 40 mg/dl, high 그 60 mg/에), family history of prema ture CHD. After evaluating of all risk factors from the each patient, total risk factors were simply co니nted by addition or s니btraction to apply for the therapy goal.
Evaluate any occurrence of the adverse drug effects of each patients d니ring the dr니g therapy by reviewing of the medical records. Also we evaluated for the levels of ala nine aminotrasferase (ALT) and aspartate aminotrans ferase (AST) as liver f니nction test, since both atorvastatin and rosuvastatin are metabolized by liver (Carrilho et al.
The aim of this study was to evaluate the efficacy and safety between rosuvastatin and atorvastatin and then the result of this study can apply for effective and safe phar macotherapy of Korean dyslipidemic patients in the f니ture. We reviewed retrospectively the total 392 medical records from the dyslipidemic patients either on atorvastatin or rosuvastatin from June 1 st, 2004 to August 31 st, 2006 in a university hospital of C City in Chungcheongbuk-do.
대상 데이터
If anyone did not meet the above conditions, they would be excluded. The 34 patients were excluded among total 392 patients in this study.
데이터처리
The statistical differences between drugs were evalu ated by ANOVA analysis. Student-Newmans-K이s method applied for post hoc analysis with adjustments of sex, dia betes m이litus, CAD and any influencing factors.
이론/모형
by ANOVA analysis. Student-Newmans-K이s method applied for post hoc analysis with adjustments of sex, dia betes m이litus, CAD and any influencing factors. Data were judged by Statistical Package for the Social Science (SPSS), 10.
성능/효과
2 mg/dL). After the each drug therapy for 6weeks, both ator vastatin and rosuvastatin decrease TC serum levels and their results of TC levels were each atorvastatin 5 mg (- 15.1%), atorvastatin 10 mg (-23.3%), rosuvastatin 5 mg (- 28.7%) and rosuvastatin 10 mg (-28.3%)(Table II). Aa a results, both atorvastatin and rosuvastatin meaningfully decrease the TC serum level.
8%), (Table II). Also the HDL-C serum level for each drug showed the increasing pattern with the decressing of Tg serum level but it was not meaningful statistically (p= 0309)(Fig. 5).
In conclusion, both atorvastatin and rosvastatin were showed the improvements of lipid profiles with a few ter- able side effects in Korean. Therefore both atorvastatin and rosuvastatin among HMG-CoA redctase inhibitors have the benefit for the treatment of Korean dyslipidemia.
In the result of this study, both atorvastatin and rosvas- tatin showed the good improvements with decreasing of LDL-C. Howeverer, rosvastatin showed meaningfully more decreasing rate compared with atorvastatin.
non-HDL-C serum levels. Their results of LDL-C levels were each atorvastatin 5 mg (-20.0%), atwastatin 10mg (-29.2%), rosuvastatin 5 mg (-35.8%) and ros니vastatin 10mg (-36.3%)(lable 3). In both atorvastatin and ros니val- statin dings were showed the improvement of non HDL-C levels and also showed meaningfully high decrements in a higher dose(P=0.
of LDL-C serum levels. Their results of LDL-C levels were each atorvastatin 5mg (4.8%), atorvastatin 10mg (0.5%), rosuvastatin 5mg (2.1%) and rosuvastatin 10mg (8.0%)(Table II). In the levels of HDL-C for each drug also showed the improvement of increasing pattern but it was not meaningful statistically (p= 0.
of Tg serum levels. Their results of Tg levels were each atorvastatin 5 mg (-2.5%), atorvastatin 10 mg (- 4.0%), rosuvastatin 5 mg (-10.5%) and rosuvastatin 10 mg (-4.8%), (Table II). Also the HDL-C serum level for each drug showed the increasing pattern with the decressing of Tg serum level but it was not meaningful statistically (p= 0309)(Fig.
참고문헌 (27)
Strutt et al, 2004 Guidelines for Hyperlipidemia Therapy, 2006
Blasetto, J. W., E. A. Stein, W. V. Brown, R. Chitra, and A. Raza (2003), 'Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups,' Am J Cardiol, 91(5A), 3C-10C; discussion10C
Carrilho, A. J., W. L. Medina, E. R. Nakandakare, and E. C. Quintao(1997), 'Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine,' Clin Pharmacol Ther, 62(1), 82-88
Davidson, M., P. Ma, E. A. Stein, A. M. Gotto, Jr., A. Raza, R. Chitra, and H. Hutchinson(2002), 'Comparison of effects on low-density lipoprotein cholesterol and highdensity lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia,' Am J Cardiol, 89 (3), 268-275
De Backer, G., E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cifkova, J. Dallongeville, S. Ebrahim, O. Faergeman, I. Graham, G. Mancia, V. Manger Cats, K. Orth- Gomer, J. Perk, K. Pyorala, J. L. Rodicio, S. Sans, V. Sansoy, U. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (2001), 'Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III),' Jama, 285(19), 2486-2497
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (2001), "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)," Jama, 285(19), 2486-2497
Sechtem, S. Silber, T. Thomsen, and D. Wood(2003), "European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice," Eur Heart J, 24(17), 1601-1610
Endo, A., Y. Tsujita, M. Kuroda, and K. Tanzawa(1977), 'Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3- hydroxy-3-methylglutaryl-coenzyme A reductase,' Eur J Biochem, 77(1), 31-36
Gagne, C. H. E. Bays, S. R. Weiss, P. Mata, K. Quinto, M. Melino, M. Cho, T. A. Musliner, and B. Gumbiner(2002), 'Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia,' Am J Cardiol, 90(10), 1084-1091
Heart Protection Study Collaborative Group (2002), 'MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial,' Lancet, 360(9326), 7-22
Japan Atherosclerosis Society (2002), 'Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of atherosclerotic cardiovascular disease.' Tokyo JAS
Jones, P., S. Kafonek, I. Laurora, and D. Hunninghake( 1998), 'Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatinin patients with hypercholesterolemia(the CURVES study),' Am J Cardiol, 81 (5), 582-587
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.(1998) 'Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.' N Engl J Med, 339, 1349-1357
Lloret, R., J. Ycas, M. Stein, and S. Haffner(2006), 'Comparison of rosuvastatin versus atorvastatin in Hispanic- Americans with hypercholesterolemia(from the STARSHIP trial),' Am J Cardiol, 98(6), 768-773
Mabuchi, H., T. Kita, M. Matsuzaki, Y. Matsuzawa, N. Nakaya, S. Oikawa, Y. Saito, J. Sasaki, K. Shimamoto, and H. Itakura (2002), 'Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT),' Circ J, 66(12), 1096-1100
Menotti, A., A. Keys, H. Blackburn, D. Kromhout, M. Karvonen, A. Nissinen, J. Pekkanen, S. Punsar, F. Fidanza, S. Giampaoli, F. Seccareccia, R. Buzina, I. Mohacek, S. Nedeljkovic, C. Aravanis, A. Dontas, H. Toshima, and M. Lanti(1996), 'Comparison of multivariate predictive power of major risk factors for coronary heart diseases in different countries: results from eight nations of the Seven Countries Study, 25-year follow-up,' J Cardiovasc Risk, 3(1), 69-75
Olsson, A. G., H. Istad, O. Luurila, L. Ose, S. Stender, J. Tuomilehto, O. Wiklund, H. Southworth, J. Pears, and J. W. Wilpshaar(2002), 'Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia,' Am Heart J, 144(6), 1044-1051
Sacks, F. M., L. A. Moye, B. R. Davis, T. G. Cole, J. L. Rouleau, D. T. Nash, M. A. Pfeffer, and E. Braunwald(1998), 'Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial,' Circulation, 97(15), 1446-1452
Scandinavian Simvastatin Survival Study Group (1994), 'Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S),' Lancet, 344(8934), 1383-1389
Shepherd, J., S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer, P. W. MacFarlane, J. H. McKillop, and C. J. Packard(1995), 'Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group,' N Engl J Med, 333(20), 1301-1307
Stamler, J., D. Wentworth, and J. D. Neaton(1986), 'Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT),' Jama, 256(20), 2823-2828
Stein E, Strutt KL, Miller E, Southworth H. (2001) 'Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolemia' Atherosclerosis (2) 90
Strutt, K. R. Caplan, H. Hutchison, A. Dane, and J. Blasetto (2004), 'More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy,' Circ J, 68(2), 107- 113
Sytkowski, P. A., R. B. D'Agostino, A. Belanger, and W. B. Kannel(1996), 'Sex and time trends in cardiovascular disease incidence and mortality: the Framingham Heart Study, 1950-1989,' Am J Epidemiol, 143(4), 338-350
※ AI-Helper는 부적절한 답변을 할 수 있습니다.